# A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)

> **NCT04756323** · PHASE2 · UNKNOWN · sponsor: **Beijing Minhai Biotechnology Co., Ltd** · enrollment: 1000 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** medium dosage inactivated SARS-CoV-2 vaccine
- **BIOLOGICAL:** high dosage inactivated SARS-CoV-2 vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04756323
- **Lead sponsor:** Beijing Minhai Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-27
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-02-28
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2021-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04756323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04756323, "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT04756323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*